Inoviq Ltd · ASX:IIQ
Inoviq — ANZSEV (November 2021)
19 slides from Inoviq's conference presentation, Nov 10, 2021
Slide 1: Introducing EXO-NET
Introducing EXO-NET Next generation exosome isolation technology Dr Emily Stein ANZSEV 10th November 2021 BARD1 Presentation November 2021 Page 1
Slide 2: Sample preparation has limited exosome research
Sample preparation has limited exosome research Limitations of existing exosome isolation methods: • Low reproducibility • Labour intensive • Time consuming (hours) • Low throughput (not automatable) • Yield and purity variable - dependent upon either size or affinity • Not scalable Limits translati
Slide 3: Introducing EXO-NET®
Introducing EXO-NET® A molecular NET (matrix) comprising eight antibodies (to common external exosome-associated proteins) with spacers and linkers that form a multilayered complex matrix with defined porosity to exclude larger particles. Magnetic Bead The EXO-NET matrix is coated onto magnetic bead
Slide 4: EXO-NET simplifies exosome capture
EXO-NET simplifies exosome capture BARD1 Presentation November 2021 Page 4
Slide 5: EXO-NET simplifies exosome capture
EXO-NET simplifies exosome capture Typical research example – Compared to column-based exosome isolation solutions (exclusion or affinity chromatography): 96 columns + 96 tip changes + multiple fraction collectors or centrifuges + + EXO-NET: 1 microtiter plate + 8 -12 tip changes + 1 magnetic plate
Slide 6: EXO-NET – superior purity
EXO-NET – superior purity EXO-NET SEC Plasma exosome preparations are free of albumin and other common serum protein contaminants, unlike size exclusion chromatography (SEC) Gel Provided by EXO-NET End User BARD1 Presentation November 2021 Page 6
Slide 7: EXO-NET - Superior speed and yield
EXO-NET - Superior speed and yield EXO-NET used for isolation of circulating tumor-derived exosomes for rapid downstream analysis Exo-NET Proven Superior Exo-NET >85% breast cancer-derived Much higher yield and faster exosomes recovered in 15 min (15 mins v 16 hours) BARD1 Presentation November 2021
Slide 8: EXO-NET exosome isolation is specific
EXO-NET exosome isolation is specific Artificial Pooled Plasma Plasma Total lysate Blank EXO-NET EXO-NET Beads CD63 CD9 Calnexin (Cell and Golgi marker) Demonstration that EXO-NETs can capture specific cell- derived exosomes and not other cell-derived vesicles BARD1 Presentation November 2021 Page 8
Slide 9: EXO-NET Competitor Comparison Testing
EXO-NET Competitor Comparison Testing BARD1 Presentation November 2021 Page 9
Slide 10: exoEasy vs EXO-NET
exoEasy vs EXO-NET 40.00 human miRNA NHP-10 exoEasy NHP-10 EXO-NET 35.00 NHP-15 exoEasy NHP-15 EXO-NET CT VALUE 30.00 25.00 20.00 15.00 let-7a miR-16 miR-21 0.2 mL Plasma BARD1 Presentation November 2021 Page 10
Slide 11: Norgen vs EXO-NET
Norgen vs EXO-NET NHP-9 Norgen 41.00 NHP-9 EXO-NET human miRNA BRC-8 Norgen 39.00 BRC-8 EXO-NET 37.00 35.00 CT VALUE 33.00 31.00 29.00 27.00 25.00 miR-16 let-7a miR-21 0.2 mL Plasma BARD1 Presentation November 2021 Page 11
Slide 12: Exo-Quick vs EXO-NET
Exo-Quick vs EXO-NET SBI NHP-9 40.00 EXO-NET NHP-9 human miRNA SBI NHP-18 EXO-NET NHP-18 35.00 CT VALUES 30.00 25.00 20.00 miR-16 miR-21 let-7a 0.2 mL Plasma BARD1 Presentation November 2021 Page 12
Slide 13: Thermo Fisher vs EXO-NET
Thermo Fisher vs EXO-NET 41.00 NHP-10 Thermo NHP-10 EXO-NET 39.00 human mRNA NHP-15 Thermo NHP-15 EXO-NET 37.00 35.00 CT VALUE 33.00 31.00 29.00 27.00 25.00 GAPDH HPRT1 KRAS 0.5 mL Plasma BARD1 Presentation November 2021 Page 13
Slide 14: Competitor Comparison Testing Conclusion
EXO-NET Competitor Comparison Testing CONCLUSION EXO-NET is either equivalent to or out-performs all competitor products tested. In addition it is faster, and scalable for high throughput applications BARD1 Presentation November 2021 Page 14
Slide 15: EXO-NET captures intact vesicles
EXO-NET captures intact vesicles 41.00 Exosomes on EXO-NET beads were incubated in the presence of RNaseA, 39.00 Triton X-100 or both combined, and 37.00 assayed by RT-PCR for miRNAs. AVERAGE CT VALUE 35.00 miRNA yields were only reduced by the 33.00 combination of RNaseA and detergent. 31.00 CONCLU
Slide 16: Conclusions
Conclusions • Simple, rapid procedure for intact exosome isolation, limited hands-on time and incubation time of 15 minutes. • Protein and nucleic acid extraction possible from the same sample. • Recovery of miRNA and mRNA is equivalent or substantially improved compared to other commercial products
Slide 17: EXO-NET® advantages
EXO-NET® advantages • Reproducible – Intra and Inter-assay • Purity – Free from contaminating non-exosome proteins • Rapid capture – 15-30 minutes • Versatile • Plasma • Urine • Saliva • Cell culture supernatant • Optimal solution for very low volume and rare samples • Downstream analysis can be per
Slide 18: Contacts
Contacts BARD1 Life Sciences Ltd 23 Normanby Road Notting Hill VIC 3168 Australia P +61 3 9548 7586 E info@bard1.com W www.bard1.com Dr Leearne Hinch | CEO E leearne@bard1.com M 0400414416 More information on EXO-NET: www.exo-net.com BARD1 Presentation November 2021 Page 18
Slide 19: Disclaimer
Disclaimer This presentation has been prepared by BARD1 Life appropriateness of the information having regard to their “believes”, or variations (including negative variations) of Sciences Limited (“BARD1” or the “Company”) based own objectives, financial situation and needs, and seek such words and